NICE Backs Pradaxa(R) (Dabigatran Etexilate) - The First Oral Anticoagulant In Over Fifty Years

Boehringer Ingelheim welcomed the National Institute for Health and Clinical Excellence (NICE)’s Final Appraisal Determination (FAD) which gives a draft recommendation that Pradaxa® (dabigatran etexilate), within its marketing authorisation, is recommended as an option for the primary prevention of venous thromboembolic events in adults who have undergone elective total hip or elective total knee replacement surgery.

More: continued here

Filed under: Blood on July 31st, 2008